Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

1.

Postlicensure safety surveillance for high-dose trivalent inactivated influenza vaccine in the Vaccine Adverse Event Reporting System, 1 July 2010-31 December 2010.

Moro PL, Arana J, Cano M, Menschik D, Yue X, Lewis P, Haber P, Martin D, Broder K.

Clin Infect Dis. 2012 Jun;54(11):1608-14. doi: 10.1093/cid/cis256. Epub 2012 Mar 22.

PMID:
22441652
2.

Adverse events after Fluzone ® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013.

Moro PL, Harrington T, Shimabukuro T, Cano M, Museru OI, Menschik D, Broder K.

Vaccine. 2013 Oct 9;31(43):4984-7. doi: 10.1016/j.vaccine.2013.08.001. Epub 2013 Aug 29.

PMID:
23994022
3.
4.

Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.

Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, Haber P, Pless RP, Mootrey G, Ellenberg SS, Braun MM, Chen RT.

MMWR Surveill Summ. 2003 Jan 24;52(1):1-24. Erratum in: MMWR Morb Mortal Wkly Rep. 2003 Feb 14;52(06):113.

5.

Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.

Haber P, Moro PL, Lewis P, Woo EJ, Jankosky C, Cano M.

Vaccine. 2016 May 11;34(22):2507-12. doi: 10.1016/j.vaccine.2016.03.048. Epub 2016 Mar 23. Review.

6.
7.

Post-licensure surveillance of trivalent live attenuated influenza vaccine in adults, United States, Vaccine Adverse Event Reporting System (VAERS), July 2005-June 2013.

Haber P, Moro PL, McNeil MM, Lewis P, Woo EJ, Hughes H, Shimabukuro TT.

Vaccine. 2014 Nov 12;32(48):6499-504. doi: 10.1016/j.vaccine.2014.09.018. Epub 2014 Sep 22.

PMID:
25258101
8.

Post-Licensure Surveillance of Trivalent Live-Attenuated Influenza Vaccine in Children Aged 2-18 Years, Vaccine Adverse Event Reporting System, United States, July 2005-June 2012.

Haber P, Moro PL, Cano M, Vellozzi C, Lewis P, Woo EJ, Broder K.

J Pediatric Infect Dis Soc. 2015 Sep;4(3):205-13. doi: 10.1093/jpids/piu034. Epub 2014 May 7.

PMID:
26407428
10.

Safety of influenza A (H1N1) 2009 monovalent vaccines - United States, October 1-November 24, 2009.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2009 Dec 11;58(48):1351-6.

11.

Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring.

Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P.

Vaccine. 2009 Mar 26;27(15):2114-20. doi: 10.1016/j.vaccine.2009.01.125. Epub 2009 Feb 6.

PMID:
19356614
12.

Post-licensure surveillance of quadrivalent live attenuated influenza vaccine United States, Vaccine Adverse Event Reporting System (VAERS), July 2013-June 2014.

Haber P, Moro PL, Cano M, Lewis P, Stewart B, Shimabukuro TT.

Vaccine. 2015 Apr 15;33(16):1987-92. doi: 10.1016/j.vaccine.2015.01.080. Epub 2015 Feb 9.

PMID:
25678241
13.

An analysis of rotavirus vaccine reports to the vaccine adverse event reporting system: more than intussusception alone?

Haber P, Chen RT, Zanardi LR, Mootrey GT, English R, Braun MM; VAERS Working Group.

Pediatrics. 2004 Apr;113(4):e353-9.

PMID:
15060267
14.

Safety and immunogenicity of 2010-2011 H1N12009-containing trivalent inactivated influenza vaccine in children 12-59 months of age previously given AS03-adjuvanted H1N12009 pandemic vaccine: a PHAC/CIHR Influenza Research Network (PCIRN) study.

Langley JM, Scheifele DW, Quach C, Vanderkooi OG, Ward B, McNeil S, Dobson S, Kellner JD, Kuhn S, Kollman T, MacKinnon-Cameron D, Smith B, Li Y, Halperin SA.

Vaccine. 2012 May 14;30(23):3389-94. doi: 10.1016/j.vaccine.2012.03.046. Epub 2012 Mar 30.

PMID:
22469860
15.
16.

Serious adverse events following receipt of trivalent inactivated influenza vaccine in Korea, 2003-2010.

Choe YJ, Cho H, Kim SN, Bae GR, Lee JK.

Vaccine. 2011 Oct 13;29(44):7727-32. doi: 10.1016/j.vaccine.2011.07.129. Epub 2011 Aug 7.

PMID:
21827815
17.

Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system.

Leroy Z, Broder K, Menschik D, Shimabukuro T, Martin D.

Vaccine. 2012 Mar 2;30(11):2020-3. doi: 10.1016/j.vaccine.2011.12.042.

PMID:
22361303
18.

A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in children 5 through 17 years of age.

Baxter R, Toback SL, Sifakis F, Hansen J, Bartlett J, Aukes L, Lewis N, Wu X, Ambrose CS.

Vaccine. 2012 Apr 19;30(19):2989-98. doi: 10.1016/j.vaccine.2012.02.039. Epub 2012 Feb 29.

19.

Reactogenicity of two 2010 trivalent inactivated influenza vaccine formulations in adults.

Leeb A, Carcione D, Richmond PC, Jacoby P, Effler PV.

Vaccine. 2011 Oct 19;29(45):7920-4. doi: 10.1016/j.vaccine.2011.08.073. Epub 2011 Aug 22.

PMID:
21864621
20.

Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age.

Rosenberg M, Sparks R, McMahon A, Iskander J, Campbell JD, Edwards KM.

Vaccine. 2009 Jul 9;27(32):4278-83. doi: 10.1016/j.vaccine.2009.05.023. Epub 2009 May 28.

PMID:
19450636

Supplemental Content

Support Center